GPCR NASDAQ
Structure Therapeutics Inc.
1W: -5.8%
1M: -38.5%
3M: -54.5%
YTD: -68.4%
1Y: -18.3%
3Y: -68.1%
$21.55
+0.45 (+2.13%)
Weekly Expected Move ±7.5%
$18
$20
$21
$23
$24
Credit Risk of going bust: lower than 80% of companies Debt: 0.5% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down 99.9%), Structure Therapeutics Inc. would be worth roughly what it owes.
Total debt $6.2M against a stock market value of $1.24B.
Distance to default 9.66 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $3.1M (short-term plus half of long-term), stock volatility 60.7%; Altman Z'' 23.53. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.01 (down 99.9%), Structure Therapeutics Inc. would be worth roughly what it owes.
Total debt $6.2M against a stock market value of $1.24B.
Distance to default 9.66 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $3.1M (short-term plus half of long-term), stock volatility 60.7%; Altman Z'' 23.53. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
7 relationships7
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2023-07-06
Earliest Filing
2026-01-05
Latest Filing
supplier: 3
licensee: 2
partner: 2
Counterparties (Filed by GPCR)
7 relationshipsCompanies named in GPCR's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Genentech, Inc. | — | licensee | Granted a non-exclusive license to manufacture and sell GNE Products containing CT-996 and paid a $100 million upfront f | 2026-01-05 | View |
| F. Hoffmann-La Roche Ltd | — | licensee | Jointly with Genentech, received a non-exclusive license to manufacture and sell GNE Products containing CT-996. | 2026-01-05 | View |
| Aconcagua Bio, Inc. | — | partner | Wholly-owned subsidiary of Structure Therapeutics Inc. entered into a collaboration agreement for drug discovery. | 2023-11-14 | View |
| Schrödinger, Inc. | — | partner | Partnered with Aconcagua Bio, Inc. to provide computational modeling and design support for novel small molecule modulat | 2023-11-14 | View |
| Shanghai Changtai Business Management Co., Ltd. | — | supplier | Landlord for Shanghai office space lease | 2023-07-06 | View |
| Shanghai Chuangzhi Space Entrepreneurship Incubator Management Co., Ltd. | — | supplier | Landlord for Shanghai laboratory space lease | 2023-07-06 | View |
| Aligos Therapeutics, Inc. | ALGS | supplier | Landlord for South San Francisco office space sublease | 2023-07-06 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-08 | Regulation FD; Other Events; Exhibits | View | |
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-06-18 | Shareholder Vote | View | |
| 2026-05-07 | Material Agreement; Earnings Release; Other Events; Exhibits | Agreement | View |
| 2026-04-15 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-03-16 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2026-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-05 | Entry into Material Definitive Agreement | Agreement | View |
| 2025-12-10 | Other Events; Financial Statements and Exhibits | View | |
| 2025-12-08 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-25 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-27 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-12-17 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2024-11-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-09-17 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Other Events; Fi | View | |
| 2024-08-27 | Departure/Election of Directors; Appointment of Officers | View | |
| 2024-08-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR